Scientific Pandemic Influenza Advisory Committee (SPI)




	DH Home




	You are here: Advisory bodies > Scientific Pandemic Influenza Advisory Committee (SPI) > Members

Subgroups


	Subgroup on modelling
	Subgroup on behaviour and communication

Review of evidence base

SPI contacts

SPI members' biographies

Dr Stephen Inglis
Director of the National Institute for Biological Standards Control (NIBSC)

Stephen Inglis is Director of the National Institute for Biological Standards and Control (NIBSC), a UK Department of Health-sponsored scientific institute focused on assuring the quality of existing and new biological medicines through applied research on safety and efficacy issues, development of related methodologies and reference materials, and testing of manufactured products for release on to the market. NIBSC plays a key international role in both seasonal and pandemic influenza vaccine development. He serves on a number of advisory committees, including the Biologicals & Vaccines Expert Advisory Group of the Commission for Human Medicines, the Joint Vaccination and Immunisation Committee, and the Joint Professional Advisory Committee to the UK Blood Services.

Prior to joining NIBSC in 2002, he spent 12 years in the biotechnology industry. He was Research Director at Cantab Pharmaceuticals from 1995 and subsequently at Xenova following its merger with Cantab in 2001. From 1980-1990 he was a lecturer in virology at the Department of Pathology, Cambridge University specialising in the molecular biology of influenza virus infection. He trained in Biochemistry and received a Ph.D. in virology from Cambridge University in 1978.

Top